РОЛь цИТОКИНОВ В РАЗВИТИИ СЕРДЕЧНО-СОСУДИСТыХ ЗАБОЛЕВАНИЙ И ОСТЕОПОРОЗА

В последние годы активно изучается роль интерлейкинов в развитии ряда широко распространённых заболеваний, таких как патология сердечно-сосудистой системы (атеросклероз, артериальная гипертензия, ишемическая болезнь сердца и др.) и остеопороз. В обзоре приводятся данные проведённых исследований, посвящённых изучению значения цитокинов при возникновении данных заболеваний.

интерлейкины, атеросклероз, сердечно-сосудистые заболевания, остеопороз, минеральная плотность костной ткани

1. Cummings S.R., Nevitt M.C. Epidemiology of hip fractures and foils. In Kleerekoper M., Krane S.M. (eds). - Clinical disorders of bone and mineral Metabolism. Mary Ann Liebert Inc., Publishers, New York. - 1989. - p. 231-36.

2. BarengoltsE.U., BermanM., KukrejaS.C., etal. Osteoporosis and coronary atherosclerosis in asymptomatic postmenopausal women. — Calcif Tissue Int. - 1998. - № 62. -p. 209-13.

3. Jorgensen L., Joakimsen O., Berntsen R., et al. Low bone mineral density is related to echogenic carotid artery plaques: a population-based study. Am J Epidemiol. - 2004. - V. 160. - № 6. - p. 549-53.

4. Kammerer СМ., Dualan A.A., Samollow P.B., et al. Bone mineral density, carotid artery intimal medial thickness, and the vitamin D receptor BsmI polymorphism in Mexican American women. - Calcif Tissue Int. - 2004. - V.75. -№4.-p. 292-8.

5. Libby P, Ridker P, Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 105: 1135-43.

6. Ridker PM. C-reactive protein, inflammation and cardiovascular disease — Clinical Update. Tex Heart Inst J. 2005; 32: 384-6. 9. Libby P. Inflammation in atherosclerosis. Nature. 2002; 420 (6917): 868-74.

7. Ramos AM, Pellanda LC, Gus I, Portal VL. Inflammatory markers of cardiovascular disease in the elderly. Arq Bras Cardiol.2009 Mar; 92(3):221-8, 227-34.

8. Libby P. Inflammation in atherosclerosis. Nature. 2002; 420 (6917): 868-74.

9. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference interval and epidemiological applications. Clin.Chem. 1997; 43 (1): 52-8.

10. Ershler WB. Interleukin-6: a cytokine for gerontologists. J Am Geriatr Soc. 1993; 41 (2): 176-81.

11. Van Snick J. Interleukin-6: an overview. Annu Rev Immunol. 1990; 8: 253-78.

12. Yamagami H, Kitagawa K, Nagai Y, Hougaku H, Sakaguchi M, KuwabaraK, etal. Higher levels of interleukin-6 are associated with lower echogenicity of carotid artery plaques. Stroke. 2004; 35 (3): 677-81.

13. Jenny NS, Tracy RP, Ogg MS, Luong LA, Kuller LH, Arnold AM, etal. In the elderly, interleukin-6 plasma levels and the — 174G>C polymorphism are associated with the development of cardiovascular disease. Arterioscler'ThrombVasc Biol. 2002; 22: 2066-71.

14. Volpato S, Guralnik JM, Ferrucci L, Balfour J, Chaves P, Fried LP, etal. Cardiovascular disease, interleukin-6, and risk of mortality in older women: the Women.s Health and Aging Study. Circulation. 2001; 103: 947-53.

15. Schomig K, Busch G, Steppich B, Sepp D, KaufmannJ , Stein A etal. Interleukin-8 is associated with circulating CD133. progenitor cells in acute myocardial infarction. Eur Heart J 2006;27:1032-1037.

16. Inoue T, Komoda H, Nonaka M, Kameda M, Uchida T, Node K. Interleukin-8 as an independent predictor of long-term clinical outcome in patients with coronary artery disease. Int J Cardiol 2008;124:319-325.

17. Panichi V, Taccola D, Rizza GM, Consani C, Ghiadoni L, Filippi C et al. Interleukin-8 is a powerful prognostic predictor of all-cause and cardiovascular mortality in dialytic patients. Nephron ClinPract 2006;102:51-58.

18. Kanda T, Hirao Y, Oshima S, Yuasa K, Taniguchi K, Nagai R et al. Interleukin-8 as a sensitive marker of unstable coronary artery disease. Am J Cardiol 1996;77:304-307.

19. Romuk E, Skrzep-Poloczek B, Wojciechowska C, Tomasik A, Birkner E, Wodniecki J et al. Selectin-P and interleukin-8 plasma levels in coronary heart disease patients. Eur J Clin Invest 2002;32:657-661.

20. Hashmi S, Zeng QT. Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coron Artery Dis 2006;17:699-706.

21. Abe Y, Kawakami M, Kuroki M, Yamamoto T, Fujii M, Kobayashi H et al. Transient rise in serum interleukin-8 concentration during acute myocardial infarction. Br Heart J 1993;70:132-134.

22. Schomig K, Busch G, Steppich B, Sepp D, Kaufmann J, Stein A et al. Interleukin-8 is associated with circulating CD133. progenitor cells in acute myocardial infarction. Eur Heart J 2006;27:1032-1037.

23. Kim CS, Park HS, Kawada T, Kim JH, Lim D, Hubbard NE et al. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int J Obes (Lond) 2006;30:1347-1355.

24. von Vietinghoff S, Ley K. Interleukin 17 in vascular inflammation.Cytokine Growth Factor Rev. 2010 Dec;21(6):463-9. Epub 2010 Nov 12.

25. Zhou RH, Shi Q, Gao HQ, Shen BJ. Changes in serum interleukin-8 and interleukin-12 levels in patients with ischemic heart disease in a Chinese population. J AtherosclerThromb 2001;8:30-32.

26. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin-10 and related cytokines and receptors. Annu Rev Imunnol. 2004; 22: 929-79.

27. Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Boersma E, Simoons Ml, et al. Serum level of antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patient with acute coronary syndromes. Circulation. 2003; 107: 2109-14.

28. Van Excel E, Gussekloo J, de Craen AJ, Bootsma- van der Wiel A, Frolich M, Westendorp RGJ. Inflammation and stroke: the Leiden 85-Plus Study. Stroke. 2002; 33: 1135-8.

29. =29Wang M, Markel TA, Meldrum DR. Interleukin 18 in the heart.Shock. 2008 Jul;30(1):3-10.

30. =30Rabkin SW. The role of interleukin 18 in the pathogenesis of hypertension-induced vascular disease.Nat ClinPractCardiovasc Med. 2009 Mar;6(3):192-9.

31. ==31Van H, Rosendaal FR. High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly. J ThrombHaemost. 2003; 1 (12): 2677-8.

32. =32Kritchevsky SB, Cesari M, Pahor M. Inflammatory markers and cardiovascular health in older adults. Cardiovasc Res. 2005; 66: 265-75.

33. =33Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation. 2003; 108: 2317-22.

34. =34Arron J, Choi Y. Bone versus immune sysem. Nature 2000;408:535-536.

35. =35Walsh MC, Kim N, Kadono Y, Rho J, et al. Osteoimmunology: Interplay Between the Immune system and Bone Metabolism. Annu. Rev. Immunol 2006;24:33-63.

36. =36Jorgensen NR. Cytokines and osteoporosis.Ugeskr Laeger.1997 Dec 29;160(1):24-8.

37. =37Edwards CJ, Williams E. The role of interleukin-6 in rheumatoid arthritis-associated osteoporosis.,Osteoporos Int. 2010 Aug;21(8):1287-93.

38. =38 McLean R.R. Proinflammatorycytokinesandosteoporosis.,Cu rrOsteoporosRep. 2009 Dec;7(4):134-9.

39. =39 Lee YM, Fujikado N, Manaka H, Yasuda H, Iwakura Y. IL-1 plays an important role in the bone metabolism under physiological conditions.ntImmunol. 2010 Oct;22(10):805-16.

40. =40Polzer K, Joosten L, Gasser J, Distler JH, Ruiz G, Baum W, Redlich K, Bobacz K, Smolen JS, van den Berg W, Schett G, Zwerina J. Interleukin-1 is essential for systemic inflammatory bone loss.Ann Rheum Dis. 2010 Jan;69(1):284-90.

41. =41Goswami J, Hernandez-Santos N, Zuniga LA, Gaffen SL. A bone-protectiverole for IL-17receptorsignaling in ovariectomy-induced bone loss. Eur J Immunol. 2009 Oct;39(10):2831-9.

42. Lubberts E, van den Bersselaar L, Oppers-Walgreen B, Schwarzenberger P, Coenen-de Roo CJ, Kolls JK, Joosten LA, van den Berg WB. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/ osteoprotegerin balance. J Immunol 2003;170:2655-2662.

43. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y, Cua DJ, Takayanagi H. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006;203:2673-2682.

44. Karouzakis E, Neidhart M, Gay RE e, et al. Molecular and cellular basis of rheumatoid joint destruction. ImmunolLett 2006;106(1):8-13.

45. Tilg H, Moschen AR, Kaser A, Pines A, Dotan I. Gut, inflammation and osteoporosis: basic and clinical concepts.Gut. 2008 May;57(5):684-94.

46. Riggs B. The mechanisms of estrogen regulation of bone resorption. J ClinInvestig 2000;106:1203- 1204.

47. Pfeilschifter J, Köditz R, Pfohl M, et al. Changes in Proinflammatory Cytokine Activity after Menopause. Endocrine Reviews 2002;23:90-119.

48. Gertz ER, Silverman NE, Wise KS, Hanson KB, Alekel DL, Stewart JW, Perry CD, Bhupathiraju SN, Kohut ML, Van Loan MD. J ClinDensitom.Contribution of serum inflammatory markers to changes in bone mineral content and density in postmenopausal women: a 1-year investigation. 2010 Jul-Sep;13(3):277-82.

49. Sun T, Wang X, Liu Z, Chen X, Zhang J. Epub 2011 Feb 23. Plasma concentrations of pro- and anti-inflammatory cytokines and outcome prediction in elderly hip fracture patients.Injury. 2011 Jul;42(7):707-13.